Literature DB >> 26943966

The role of dopamine in modulation of Th-17 immune response in multiple sclerosis.

Mikhail Melnikov1, Olga Belousova2, Vladimir Murugin3, Мikhail Pashenkov3, Alexey Boyко2.   

Abstract

Neuromediators may modulate neuroinflammation, particularly in multiple sclerosis (MS). We investigated the effects of dopamine (DA) on the pro-inflammatory Th17-branch of immunity in 43 patients with relapsing-remitting MS and 20 healthy subjects. Serum DA was lower in MS relapse, whereas percentages of blood CD4(+)CD26(+)CD161(+)CD196(+) Th17-cells and production of interleukin-17 (IL-17) and interferon-gamma by anti-CD3/anti-CD28-stimulated peripheral blood mononuclear cells (PBMC) were higher in MS relapse than in remission or healthy subjects. DA suppressed IL-17 production by PBMC from MS patients and healthy subjects. The suppressive effect of DA was abolished in the presence of an antagonist of D2-like receptors (sulpiride). These data suggest an anti-inflammatory role for DA in MS.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dopamine; Multiple sclerosis; Neuroimmunomodulation; Th17-cells

Mesh:

Substances:

Year:  2016        PMID: 26943966     DOI: 10.1016/j.jneuroim.2016.01.020

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

1.  Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Tracy Greer; Bruce Grannemann; Abigail Soyombo; Taryn L Mayes; A John Rush; Madhukar H Trivedi
Journal:  Psychoneuroendocrinology       Date:  2017-01-24       Impact factor: 4.905

2.  Multiple sclerosis: Repurposing dopaminergic drugs for MS--the evidence mounts.

Authors:  Franca Marino; Marco Cosentino
Journal:  Nat Rev Neurol       Date:  2016-03-29       Impact factor: 42.937

3.  Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Tracy L Greer; Taryn L Mayes; Madhukar H Trivedi
Journal:  Brain Behav Immun       Date:  2017-07-08       Impact factor: 7.217

4.  Mouse T cells express a neurotransmitter-receptor signature that is quantitatively modulated in a subset- and activation-dependent manner.

Authors:  Kenneth M Rosenberg; Nevil J Singh
Journal:  Brain Behav Immun       Date:  2019-04-03       Impact factor: 7.217

Review 5.  Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions.

Authors:  Mikhail Melnikov; Vladimir Rogovskii; Alexey Boykо; Mikhail Pashenkov
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-23       Impact factor: 4.147

Review 6.  The potential roles of amino acids and their major derivatives in the management of multiple sclerosis.

Authors:  Somayeh Pashaei; Reza Yarani; Pantea Mohammadi; Mohammad Sajad Emami Aleagha
Journal:  Amino Acids       Date:  2022-04-26       Impact factor: 3.520

Review 7.  Targeting the Dopaminergic System in Autoimmunity.

Authors:  Pia M Vidal; Rodrigo Pacheco
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-19       Impact factor: 4.147

Review 8.  Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.

Authors:  Carla Melisa Chackelevicius; Sabrina Eliana Gambaro; Claudio Tiribelli; Natalia Rosso
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

Review 9.  Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence.

Authors:  Elisa Storelli; Niccolò Cassina; Emanuela Rasini; Franca Marino; Marco Cosentino
Journal:  Front Neurol       Date:  2019-01-24       Impact factor: 4.003

Review 10.  Serotonin: A mediator of the gut-brain axis in multiple sclerosis.

Authors:  Tsveta S Malinova; Christine D Dijkstra; Helga E de Vries
Journal:  Mult Scler       Date:  2017-11-09       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.